Synthetic Probes of Protein Prenylation
蛋白质异戊二烯化的合成探针
基本信息
- 批准号:6434588
- 负责人:
- 金额:$ 26.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-05-01 至 2006-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Synthetic Probes of Protein Prenylation:
Covalent modification by isoprenoid lipids prenyIation) is a critical
post-translational event for many proteins involved in cellular signaling. The
discovery that the members of the Ras family of protooncogenes are modified by
the farnesyl isoprenoid (farnesylation), and that prenylation is required for
the oncogenic forms of these proteins to express their transforming potential,
has led to intense investigation of protein-farnesyltransferase (FTase)
inhibitors (FTIs) as promising cancer chemotherapeutic agents. However, recent
developments have made it clear that the mechanism of FTI action is
unexpectedly complex, although it involves inhibition of FTase. In addition,
the contribution of isoprenoid lipids to the overall biology of Ras is
incompletely understood. Therefore, a key to applying FTase-based
pharmacological intervention is a thorough understanding of the in vivo
farnesylation pathways. Knowledge of the substrate specificity for FTase, and
the cellular function of the prenyl moiety are critical to improving the design
of future FTIs. The central hypothesis of this study is that the prenyl group
plays an active role in directing both post-translational processing and
cellular membrane localization of prenylated proteins. An important corollary
to this hypothesis is that modifications to the prenyl structure may lead to
significant, biologically relevant effects on the activity of the unnaturally
prenylated protein. We have synthesized FPP analogs that are transferred to
oncogenic Ras but fail to support transformation. These molecules are leads for
a unique class of potential anti-cancer: therapeutics we term RFIs (Ras
function inhibitors). The specific aims of this project are: 1) specifically
substituted unnatural analogs of farnesyl pyrophosphate and the homologous
isoprenoid geranylgeranyl pyrophosphate will be synthesized in a combinatorial
scheme; 2) these compounds will be screened as substrates or inhibitors of
FTase and the closely related enzyme geranylgeranyltransferase I; 3) building
upon promising preliminary results in this area, an in vivo isoprenoid
structure-function relationship will be established by replacing the H-Ras
farnesyl group with a select subset of the analogs available from the studies
described in specific aim 1 and 2 and analyzing their biological functions
following microinjection into Xenopus oocytes. The results of these
experiments will provide further insight into the mechanisms of Ras processing
transformation, a greater understanding of the specific functions of the H-Ras
farnesyl group in vivo, and fruitful directions for improvements in FTIs as
well as novel transferable analogs which might act as RFIs.
描述(由申请人提供):蛋白质异戊二烯化的合成探针:
类异戊二烯脂质(异戊二烯化)的共价修饰是一个关键
许多参与细胞信号转导的蛋白质的翻译后事件。这
发现原癌基因 Ras 家族的成员被修饰
法呢基异戊二烯(法呢基化),并且需要异戊二烯化
这些蛋白质的致癌形式表达其转化潜力,
引发了对蛋白质法呢基转移酶(FTase)的深入研究
抑制剂(FTIs)作为有前途的癌症化疗药物。然而,最近
事态发展已经表明,FTI 的作用机制是
尽管它涉及 FTase 的抑制,但出乎意料地复杂。此外,
类异戊二烯脂质对 Ras 整体生物学的贡献是
不完全理解。因此,应用基于 FTase 的关键
药物干预是对体内的透彻了解
法尼基化途径。了解 FTase 底物特异性,以及
异戊二烯部分的细胞功能对于改进设计至关重要
未来的 FTI。本研究的中心假设是异戊二烯基团
在指导翻译后处理和
异戊二烯化蛋白质的细胞膜定位。一个重要的推论
这一假设的前提是对异戊二烯结构的修饰可能会导致
对非自然活动的显着的、生物学相关的影响
异戊二烯化蛋白质。我们合成了 FPP 类似物,并将其转移到
致癌 Ras 但不能支持转化。这些分子是
一类独特的潜在抗癌疗法:我们称之为 RFI(Ras
功能抑制剂)。该项目的具体目标是:1)具体
法尼基焦磷酸的取代非天然类似物及其同源物
类异戊二烯香叶基香叶基焦磷酸将以组合方式合成
方案; 2) 这些化合物将被筛选作为底物或抑制剂
FTase 和密切相关的酶香叶基香叶基转移酶 I; 3)建筑
根据该领域有希望的初步结果,体内类异戊二烯
通过替换H-Ras建立结构-功能关系
法呢基团以及研究中可用的类似物的精选子集
具体目标1和2中描述并分析其生物学功能
显微注射到非洲爪蟾卵母细胞后。这些结果
实验将进一步深入了解 Ras 处理机制
转化,更好地了解 H-Ras 的具体功能
体内法呢基团,以及 FTI 改进的富有成果的方向
以及可能充当 RFI 的新型可转移类似物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
H Peter Spielmann其他文献
H Peter Spielmann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('H Peter Spielmann', 18)}}的其他基金
STRUCTURE OF PSORALEN MODIFIED DNA OLIGOMER BY NMR
补骨脂素修饰 DNA 寡聚物的 NMR 结构
- 批准号:
3046458 - 财政年份:1993
- 资助金额:
$ 26.59万 - 项目类别:
STRUCTURE OF PSORALEN MODIFIED DNA OLIGOMER BY NMR
补骨脂素修饰 DNA 寡聚物的 NMR 结构
- 批准号:
2169528 - 财政年份:1993
- 资助金额:
$ 26.59万 - 项目类别:
相似海外基金
O6-Alkylguanine-DNA Alkyltransferase Repair of Modified Pyrimidines
O6-烷基鸟嘌呤-DNA 烷基转移酶修复修饰的嘧啶
- 批准号:
498189-2016 - 财政年份:2016
- 资助金额:
$ 26.59万 - 项目类别:
University Undergraduate Student Research Awards
MICRO-PET IMAGING OF ALKYLGUANINE-DNA ALKYLTRANSFERASE (AGT)
烷基鸟嘌呤-DNA 烷基转移酶 (AGT) 的显微 PET 成像
- 批准号:
7358332 - 财政年份:2006
- 资助金额:
$ 26.59万 - 项目类别:
Imaging of O6-Alkylguanine-DNA Alkyltransferase
O6-烷基鸟嘌呤-DNA 烷基转移酶的成像
- 批准号:
6942764 - 财政年份:2002
- 资助金额:
$ 26.59万 - 项目类别:
Imaging of O6-Alkylguanine-DNA Alkyltransferase
O6-烷基鸟嘌呤-DNA 烷基转移酶的成像
- 批准号:
6542181 - 财政年份:2002
- 资助金额:
$ 26.59万 - 项目类别:
Imaging of O6-Alkylguanine-DNA Alkyltransferase
O6-烷基鸟嘌呤-DNA 烷基转移酶的成像
- 批准号:
6793233 - 财政年份:2002
- 资助金额:
$ 26.59万 - 项目类别:
Imaging of O6-Alkylguanine-DNA Alkyltransferase
O6-烷基鸟嘌呤-DNA 烷基转移酶的成像
- 批准号:
6667313 - 财政年份:2002
- 资助金额:
$ 26.59万 - 项目类别:
UB-PROTEOLYSIS OF ALKYLTRANSFERASE IN GLIOMA THERAPY
神经胶质瘤治疗中烷基转移酶的 UB 蛋白水解
- 批准号:
6489201 - 财政年份:1998
- 资助金额:
$ 26.59万 - 项目类别:
UB-PROTEOLYSIS OF ALKYLTRANSFERASE IN GLIOMA THERAPY
神经胶质瘤治疗中烷基转移酶的 UB 蛋白水解
- 批准号:
2856463 - 财政年份:1998
- 资助金额:
$ 26.59万 - 项目类别:
UB-PROTEOLYSIS OF ALKYLTRANSFERASE IN GLIOMA THERAPY
神经胶质瘤治疗中烷基转移酶的 UB 蛋白水解
- 批准号:
6137608 - 财政年份:1998
- 资助金额:
$ 26.59万 - 项目类别:
UB-PROTEOLYSIS OF ALKYLTRANSFERASE IN GLIOMA THERAPY
神经胶质瘤治疗中烷基转移酶的 UB 蛋白水解
- 批准号:
2488588 - 财政年份:1998
- 资助金额:
$ 26.59万 - 项目类别: